Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-acetyltryptophan is a naturally occurring small molecule derivative of the amino acid tryptophan. It functions as an inhibitor of the neurokinin 1 receptor (NK1R), the primary receptor for the neuropeptide substance P. Research has explored its potential neuroprotective effects, particularly in models of Parkinson's disease, where it appears to reduce neuroinflammation and preserve blood-brain barrier integrity. Historically, salts of N-acetyltryptophan were investigated for treating psychiatric disorders such as depression and manic-depressive psychoses. Currently, it is widely used as a research reagent, a pharmaceutical excipient, and an impurity reference standard (Tryptophan Related Compound B).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-acetyltryptophan.